Mark Lang

Professor

University of Oklahoma Health Sciences Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Identifying the drivers of wildlife immunity is critical for assessing stressor impacts and zoonotic risks. However, such studies are limited by logistical challenges of wildlife research and lack of species-specific reagents. We adapt flow cytometry, typically confined to laboratory settings, to field settings to profile cellular immunity with small blood volumes and extended sample holding times. We apply these methods to analyze immune cell seasonality in migratory Mexican free-tailed bats ( Tadarida brasiliensis ). We confirmed four antibodies recognizing CD3, CD79a, MHCII, and CD11b that were originally validated in Egyptian fruit bats ( Rousettus aegyptiacus ), allowing us to quantify T and B cells, macrophages, and neutrophils, respectively. Flow cytometry outperformed hematology in quantifying leukocyte profiles and revealed pronounced immune cell seasonality. Adaptive cells steadily increased between spring and fall migration. Neutrophils were most abundant during the reproductive period and decreased during migrations, whereas B cells were most abundant after reproduction and before fall migration; granulocytes as a whole, macrophages, and T cells had no seasonality. Females had more B cells than males but did not differ in other cells. Our findings lay the groundwork for applying flow cytometry to field studies of wildlife and provide important insights into the seasonality of bat immunity.

Year:

2026

Clostridioides difficile remains a common source of nosocomial infection resulting in a wide range of clinical outcomes and for which there is no vaccine and limited therapeutic options. C. difficile Toxin B (TcdB)-specific IgG is the best correlate of protection against severe and recurrent disease. However, there are very few therapeutic IgG fully human monoclonal antibodies (hmAbs) that have shown efficacy thus far. We therefore hypothesized that the memory B cell (Bmem) compartment of individuals who have recovered from infection may be dominated by non-protective IgG molecules but encode some antibodies that are protective. We therefore produced hmAbs from a library of Bmem-encoded IgG1 sequences. Most TcdB-specific hmAbs displayed low affinity binding and poor neutralization of TcdB in vitro while a few hmAbs had high affinity binding and good TcdB neutralization. The results correlated with in vivo studies in which high affinity, TcdB-neutralizing hmAbs provided moderate protection of C57Bl/6 mice against C. difficile disease. Similar protection was observed in Tg32 mice expressing the human FcRn transgene, indicating that gut delivery of hmAb did not account for limited efficacy. Although non-protective antibody sequences dominate the repertoire, human Bmem cells may be a good source of therapeutic hmAbs for C. difficile treatment.

Year:

2025

Year:

2024

Purpose: Granulocyte colony stimulating factor (GCSF) enhances colon cancer development. This study defines the prevalence and effects of increased GCSF signaling in human colon cancers and investigates GCSF inhibition as an immunotherapeutic strategy against metastatic colon cancer. Experimental Design: Patient samples were used to evaluate GCSF and GCSF receptor (GCSFR) levels by immunohistochemistry with sera used to measure GCSF levels. PBMCs were used to assess the rate of GCSFR+ T cells and interferon γ (IFNγ) responses to chronic ex vivo GCSF. An immune competent mouse model of peritoneal metastasis (MC38 cells in C57Bl/6J) was used to determine the effects of GCSF inhibition (αGCSF) on survival and the tumor microenvironment (TME) with flow and mass cytometry. Results: GCSF and GCSFR are increased in human colon cancer samples as compared to patient-matched normal colon. High patient serum GCSF is associated with increases in markers of poor prognosis, (e.g., VEGF, IL6). Circulating T cells from patients express GCSFR at double the rate of T cells from controls. Prolonged GCSF exposure decreases T cell IFNγ production. Treatment with αGCSF shifts both the adaptive and innate compartments of the TME and increases survival (HR=0.46, p=0.0237) and tumor T cell infiltration, activity, and IFNγ response with greater effects in female mice. A negative correlation exists between serum GCSF levels and tumor infiltrating T cells in patient samples from women. Conclusions: These findings support GCSF as an immunotherapeutic target against colon cancer with greater potential benefit in women.

Year:

2024

Year:

2023

Collaborators (2)

Maureen Cox

Assistant Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Daniel Becker

Assistant Professor

University of Oklahoma

UNITED STATES
View details